- Home
- AVTX vs BLUE Comparison
AVTX vs BLUE Comparison
Compare AVTX & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- BLUE
- Stock Information
- Founded
- AVTX 2011
- BLUE 1992
- Country
- AVTX United States
- BLUE United States
- Employees
- AVTX N/A
- BLUE N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- BLUE Health Care
- Exchange
- AVTX Nasdaq
- BLUE Nasdaq
- Market Cap
- AVTX 90.9M
- BLUE 76.9M
- IPO Year
- AVTX 2015
- BLUE 2013
- Fundamental
- Price
- AVTX $9.09
- BLUE $7.66
- Analyst Decision
- AVTX Strong Buy
- BLUE Hold
- Analyst Count
- AVTX 4
- BLUE 9
- Target Price
- AVTX $33.00
- BLUE $49.14
- AVG Volume (30 Days)
- AVTX 141.8K
- BLUE 709.2K
- Earning Date
- AVTX 11-07-2024
- BLUE 11-14-2024
- Dividend Yield
- AVTX N/A
- BLUE N/A
- EPS Growth
- AVTX N/A
- BLUE N/A
- EPS
- AVTX N/A
- BLUE N/A
- Revenue
- AVTX $820,000.00
- BLUE $53,120,000.00
- Revenue This Year
- AVTX N/A
- BLUE $152.71
- Revenue Next Year
- AVTX N/A
- BLUE $233.91
- P/E Ratio
- AVTX N/A
- BLUE N/A
- Revenue Growth
- AVTX N/A
- BLUE 144.50
- 52 Week Low
- AVTX $3.95
- BLUE $5.80
- 52 Week High
- AVTX $34.46
- BLUE $38.40
- Technical
- Relative Strength Index (RSI)
- AVTX 37.40
- BLUE 47.35
- Support Level
- AVTX $9.00
- BLUE $5.97
- Resistance Level
- AVTX $9.99
- BLUE $9.80
- Average True Range (ATR)
- AVTX 0.89
- BLUE 2.01
- MACD
- AVTX -0.01
- BLUE 0.01
- Stochastic Oscillator
- AVTX 27.07
- BLUE 17.92
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.